Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PHGDH | O43175 | 1/20 | 0.35 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14155850 | 0.95 | SIGMAR1 (0.51) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL4544710 | 0.93 | SIGMAR1 (0.54) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL20256063 | 0.93 | SIGMAR1 (0.54) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL18053620 | 0.91 | SIGMAR1 (0.45) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL11916112 | 0.90 | SIGMAR1 (0.42) | SIGMAR1TSHRGAANPSR1MEN1 | |
| SCHEMBL14944853 | 0.89 | SIGMAR1 (0.47) | SIGMAR1TSHRGAAPHGDHMGLL | |
| SCHEMBL117945 | 0.88 | SIGMAR1 (0.41) | SIGMAR1TSHRGAAMEN1KMT2A | |
| SCHEMBL24410805 | 0.84 | SIGMAR1 (0.38) | SIGMAR1TSHRGAA | |
| SCHEMBL11916119 | 0.83 | SIGMAR1 (0.37) | SIGMAR1MEN1KMT2A | |
| SCHEMBL16254537 | 0.82 | KDM4E (0.43) | SIGMAR1POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348471-A1 | BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | ZHEJIANG HUAHAI PHARMACEUTICAL CO., LTD. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230148450-A9 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | AMGEN INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| US-11034698-B2 | Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators | GENENTECH, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | AMGEN INC. (US) | 2020-04-28 | — | — | US | disclosed |
| US-20200123166-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | GENENTECH, INC. (US) | 2020-04-23 | — | — | US | disclosed |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2019-08-01 | — | — | US | disclosed |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2015-10-29 | — | — | US | disclosed |
| US-9072696-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9072696-B2 | Cyclic peptides and use as medicines | NOVARTIS AG (CH) | 2015-07-07 | — | — | US | disclosed |
| US-9012452-B2 | Processes for making cyclopropyl amide derivatives and intermediates associated therewith | ASTRAZENECA AB (SE) | 2015-04-21 | — | — | US | disclosed |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | NOVARTIS AG (CH) | 2014-05-15 | — | — | US | disclosed |
| US-20130172560-A1 | PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH | ASTRAZENECA AB (SE) | 2013-07-04 | — | — | US | disclosed |
| WO-2011102794-A1 | PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH | ASTRAZENECA AB (SE) | 2011-08-25 | — | — | WO | disclosed |
| EP-2125748-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | AstraZeneca AB (SE) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008075068-A2 | ACYLAMINOPYRAZOLES AS FGFR INHIBITORS | ASTRAZENECA AB (SE) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | SIGMAR1 4382/4885TSHR 2318/4885GAA 4392/4885 |
| US-11034698-B2 | Pyrazolo[ 1,5a]pyrimidine derivatives as IRAK4 modulators | IRAK4, IRAK1, IRAK2 | SIGMAR1 2713/4885TSHR 3222/4885GAA 4196/4885 |
| US-11129832-B2 | Biheteroaryl compounds and uses thereof | BCHE, SNCA, HAX1 | SIGMAR1 1145/4885TSHR 1827/4885GAA 983/4885 |
| US-20130172560-A1 | PROCESSES FOR MAKING CYCLOPROPYL AMIDE DERIVATIVES AND INTERMEDIATES ASSOCIATED THEREWITH | HRH4, HRH2, HRH3 | SIGMAR1 197/4885TSHR 419/4885GAA 1285/4885 |
| US-20230348471-A1 | BRUTON'S TYROSINE KINASE INHIBITOR AND PREPARATION METHOD THEREFOR | BTK, SYK, LCK | SIGMAR1 4788/4885TSHR 3190/4885GAA 1436/4885 |
| US-10632128-B2 | Compounds that inhibit Mcl-1 protein | MCL1, BCL9, BCL2L1 | SIGMAR1 4135/4885TSHR 4722/4885GAA 2868/4885 |
| US-20140134132-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, FKBP1B | SIGMAR1 2565/4885TSHR 2177/4885GAA 3470/4885 |
| US-20190233441-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | SIGMAR1 1063/4885TSHR 2621/4885GAA 3271/4885 |
| US-20150306172-A1 | CYCLIC PEPTIDES AND USE AS MEDICINES | PPIF, VIP, MAVS | SIGMAR1 2530/4885TSHR 2159/4885GAA 2961/4885 |
| US-20230148450-A9 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | SIGMAR1 310/4885TSHR 2669/4885GAA 990/4885 |
| US-20200123166-A1 | PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS | IRAK4, IRAK1, IRAK2 | SIGMAR1 2713/4885TSHR 3222/4885GAA 4196/4885 |
| US-20200188397-A1 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, HAX1 | SIGMAR1 1145/4885TSHR 1827/4885GAA 983/4885 |
| US-11224601-B1 | Compounds that inhibits MCL-1 protein | MCL1, BCL9, BCL2L1 | SIGMAR1 4135/4885TSHR 4716/4885GAA 2803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.